12/2
08:04 am
dare
Dare Bioscience (NASDAQ:DARE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Low
Report
Dare Bioscience (NASDAQ:DARE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
12/1
08:00 am
dare
Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization
High
Report
Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization
11/24
08:00 am
dare
Daré Bioscience Receives $3.6 Million in Additional Grant Funding
Low
Report
Daré Bioscience Receives $3.6 Million in Additional Grant Funding
11/22
07:30 am
dare
Daré Bioscience, Inc. (DARE) Discusses DARE to PLAY Sildenafil Cream as a Treatment Option for Female Genital Arousal Concerns Transcript [Seeking Alpha]
High
Report
Daré Bioscience, Inc. (DARE) Discusses DARE to PLAY Sildenafil Cream as a Treatment Option for Female Genital Arousal Concerns Transcript [Seeking Alpha]
11/12
08:37 am
dare
Earnings To Watch: Dare Bioscience Inc (DARE) Reports Q3 2025 Result [Yahoo! Finance]
Medium
Report
Earnings To Watch: Dare Bioscience Inc (DARE) Reports Q3 2025 Result [Yahoo! Finance]
11/11
08:00 am
dare
Daré Bioscience Highlights Commercial Launch Readiness for DARE to PLAY™ Sildenafil Cream; November 17th Webinar to Feature Leading Clinicians Discussing Clinical Data and Potential Impact in Women’s Sexual Health
Low
Report
Daré Bioscience Highlights Commercial Launch Readiness for DARE to PLAY™ Sildenafil Cream; November 17th Webinar to Feature Leading Clinicians Discussing Clinical Data and Potential Impact in Women’s Sexual Health
11/6
08:00 am
dare
Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025
Low
Report
Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025
11/3
08:00 am
dare
Daré Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment
Low
Report
Daré Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment
10/6
08:00 am
dare
Daré Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Diso
Medium
Report
Daré Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Diso
9/24
08:00 am
dare
Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research
Medium
Report
Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research